Phaseline

Companies › Abcuro

Abcuro: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ulviprubart (ABC008)–Phase 2Inclusion Body Myositis (IBM)Jan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06450886Ulviprubart (ABC008)Phase 2Inclusion Body Myositis (IBM)NeurologyJan 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Tiziana Life Sciences Keros Therapeutics Acumen Pharmaceuticals Dianthus Therapeutics Y-mAbs Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.